Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trialAssuntina G. Sacco, Ezra E.W. Cohen, Francis P. Worden et al.|The Lancet Oncology|2021Cited by 257
Rapid Development of Salivary Gland Carcinomas upon Conditional Expression of K-ras Driven by the Cytokeratin 5 PromoterAna R. Raimondi, Alfredo Molinolo|American Journal Of Pathology|2006Cited by 39